Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Reviva Pharmaceuticals (RVPH)

July 11, 2024 10:33 AM EDT Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $14.00 price target on Reviva Pharmaceuticals (NASDAQ: RVPH).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login